Building the Future of Structural Heart Intervention.
Shanghai MicroPort CardioFlow Medtech Co., Ltd. is a medical technology company dedicated to the research, development and commercialization of innovative solutions for structural heart disease.
The company operates as part of the MicroPort Group, which was founded in Shanghai in 1998 and has developed into an international medical technology organization with activities across multiple therapeutic areas.
CardioFlow focuses on advanced transcatheter technologies for structural heart interventions, including transcatheter aortic valve implantation (TAVI/TAVR) and other minimally invasive cardiovascular therapies.
